Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
obinutuzumab leukocyte surface antigen leu-16 NA Successful target TTD , DGIDB Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Hematologic Neoplasms[MeSHID:D019337]		 28.29 approved unknown
obinutuzumab b-lymphocyte antigen cd20 biotech NA drugbank , DGIDB Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Hematologic Neoplasms[MeSHID:D019337]		 28.29 approved,investigational antibody,inhibitor
obinutuzumab b-lymphocyte antigen cd20 biotech NA drugbank , DGIDB Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Hematologic Neoplasms[MeSHID:D019337]		 28.29 approved,investigational antibody
obinutuzumab leukocyte surface antigen leu-16 NA Successful target TTD , DGIDB Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Hematologic Neoplasms[MeSHID:D019337]		 28.29 approved inhibitor
obinutuzumab leukocyte surface antigen leu-16 NA Successful target TTD , DGIDB Chronic Lymphocytic Leukemia[MeSHID:D015451]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Hematologic Neoplasms[MeSHID:D019337]		 28.29 approved antibody
click here to return to the previous page